Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Artigo em Alemão | MEDLINE | ID: mdl-28470638

RESUMO

Massive intraoperative bleeding is a major and potentially life-threatening complication during surgical procedures. The lethal triade of hemorrhagic shock with metabolic acidosis, hypothermia and coagulopathy enhances bleeding tendency. Avoiding this vitious circle requires a well-structured and standardized procedure. Primary goals include the maintenance of adequate tissue oxygenation, restauration of proper coagulatory function, normothermia and homeostasis of acid-base and electrolyte balance. In the present article, these therapeutic goals and their pathophysiological background are illustrated with a clinical case example.


Assuntos
Perda Sanguínea Cirúrgica/prevenção & controle , Substitutos Sanguíneos/administração & dosagem , Transfusão de Sangue/métodos , Monitorização Intraoperatória/métodos , Transfusão de Sangue Autóloga , Estudos de Casos e Controles , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
2.
Int J Pharm ; 427(2): 354-7, 2012 May 10.
Artigo em Inglês | MEDLINE | ID: mdl-22348875

RESUMO

A novel liposome-encapsulated hemoglobin/silica nanoparticle (LEHSN) was fabricated by a water-in-oil-in-water (W/O/W) double emulsion approach. Bovine hemoglobin (Hb) was first adsorbed onto the surfaces of silica nanoparticles (SNs), and then the complex of Hb/SNs was encapsulated by liposome to form LEHSN which has a core-shell supramolecular structure. On the one hand, liposomes built a cell membrane-like environment for the controlled release of Hb. On the other hand, SNs which act as rigid core provide a supported framework for lecithin membrane, and enhance the stability of liposomes. In comparison with liposome-encapsulated Hb (LEH), LEHSN shows substantially enhanced stability and improved release property of Hb in vitro. This study highlights the potential of the novel LEHSN as an oxygen carrier for pharmaceutical applications.


Assuntos
Substitutos Sanguíneos/administração & dosagem , Hemoglobinas/administração & dosagem , Oxigênio/administração & dosagem , Adsorção , Animais , Substitutos Sanguíneos/farmacocinética , Bovinos , Coloides , Preparações de Ação Retardada , Composição de Medicamentos , Estabilidade de Medicamentos , Emulsões , Hemoglobinas/farmacocinética , Lecitinas/química , Lipossomos , Membranas Artificiais , Microscopia Eletrônica de Transmissão , Nanopartículas , Tamanho da Partícula , Dióxido de Silício , Espectroscopia de Infravermelho com Transformada de Fourier
3.
Artif Organs ; 33(2): 146-52, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19178459

RESUMO

Clinical application of artificial oxygen carriers as a substitute for blood transfusion has long been expected to solve some of the problems associated with blood transfusion. Use for oxygen delivery treatment for ischemic disease by oxygen delivery has also been examined. These prospective applications of artificial oxygen carriers are, however, still in development. We have developed liposome-encapsulated hemoglobin (LEH), developmental code TRM-645, using technologies for encapsulation of concentrated hemoglobin (Hb) with high encapsulation efficiency as well as surface modification to achieve stability in circulating blood and a long shelf life. We have confirmed the basic efficacy and safety of TRM-645 as a red blood cell substitute in studies on the efficacy of oxygen delivery in vivo, and the safety of TRM-645 has been studied in some animal species. We are now examining various issues related to clinical studies, including further preclinical studies, management of manufacturing and the quality assurance for the Hb solution and liposome preparations manufactured by the GMP facility.


Assuntos
Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/farmacologia , Animais , Substitutos Sanguíneos/química , Substitutos Sanguíneos/farmacocinética , Ensaios Clínicos como Assunto , Avaliação Pré-Clínica de Medicamentos , Estabilidade de Medicamentos , Humanos , Lipossomos , Oxigênio/metabolismo
4.
Rev Med Chir Soc Med Nat Iasi ; 113(2): 339-44, 2009.
Artigo em Romano | MEDLINE | ID: mdl-21495338

RESUMO

Blood transfusion is usually meant to lower morbidity and mortality rates. Allogenous blood transfusion implies certain risks that can be avoided by autologous blood transfusions techniques including: preoperatory autologous blood donation, acute normovolemic hemodilution, intraoperatory and postoperatory blood salvage. Preoperatory blood donation and acute normovolemic hemodilution are used for planned interventions with an estimated blood loss higher than 20% of blood volume. These methods imply Erythropoietin and iron treatment. Intraoperatory and postoperatory blood salvage is performed by personnel trained in blood donation, handling and storage. Autologous blood transfusions are used for certain surgical procedures that commonly require transfusions: orthopedic surgery, radical prostatectomy, cardiovascular surgery, organ transplantation. An alternative to allogenous blood transfusion is the use of artificial oxygen transporters: human or animal hemoglobin solutions or pefluorocarbonate solutions. These solutions do not require cross reactions, do not carry diseases and are generally well tolerated and easily stored in the operating room, ambulance and other transport means. They have however a slight degree of toxicity.


Assuntos
Transfusão de Sangue , Cuidados Pré-Operatórios , Doadores de Sangue , Substitutos Sanguíneos/administração & dosagem , Transfusão de Sangue/métodos , Transfusão de Sangue Autóloga/métodos , Eritropoetina/administração & dosagem , Hemodiluição/métodos , Humanos , Cuidados Intraoperatórios , Ferro/administração & dosagem , Cloreto de Potássio/administração & dosagem , Cuidados Pré-Operatórios/métodos , Transplante Homólogo
5.
Circulation ; 117(15): 1982-90, 2008 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-18391111

RESUMO

BACKGROUND: One of the major obstacles hindering the clinical development of a cell-free, hemoglobin-based oxygen carrier (HBOC) is systemic vasoconstriction. METHODS AND RESULTS: Experiments were performed in healthy mice and lambs by infusion of either murine tetrameric hemoglobin (0.48 g/kg) or glutaraldehyde-polymerized bovine hemoglobin (HBOC-201, 1.44 g/kg). We observed that intravenous infusion of either murine tetrameric hemoglobin or HBOC-201 induced prolonged systemic vasoconstriction in wild-type mice but not in mice congenitally deficient in endothelial nitric oxide (NO) synthase (NOS3). Treatment of wild-type mice by breathing NO at 80 ppm in air for 15 or 60 minutes or with 200 ppm NO for 7 minutes prevented the systemic hypertension induced by subsequent intravenous administration of murine tetrameric hemoglobin or HBOC-201 and did not result in conversion of plasma hemoglobin to methemoglobin. Intravenous administration of sodium nitrite (48 nmol) 5 minutes before infusion of murine tetrameric hemoglobin also prevented the development of systemic hypertension. In awake lambs, breathing NO at 80 ppm for 1 hour prevented the systemic hypertension caused by subsequent infusion of HBOC-201. CONCLUSIONS: These findings demonstrate that HBOC can cause systemic vasoconstriction by scavenging NO produced by NOS3. Moreover, in 2 species, inhaled NO administered before the intravenous infusion of HBOC can prevent systemic vasoconstriction without causing methemoglobinemia.


Assuntos
Substitutos Sanguíneos/uso terapêutico , Hemoglobinas/uso terapêutico , Hipertensão/prevenção & controle , Óxido Nítrico/uso terapêutico , Vasoconstrição/efeitos dos fármacos , Vasodilatadores/uso terapêutico , Administração por Inalação , Animais , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/toxicidade , Transfusão de Sangue , Avaliação Pré-Clínica de Medicamentos , Hemodinâmica/efeitos dos fármacos , Hemoglobinas/administração & dosagem , Hemoglobinas/toxicidade , Hipertensão/induzido quimicamente , Infusões Intravenosas , Metemoglobinemia/prevenção & controle , Camundongos , Camundongos Knockout , Óxido Nítrico/administração & dosagem , Óxido Nítrico Sintase Tipo II/deficiência , Óxido Nítrico Sintase Tipo II/genética , Óxido Nítrico Sintase Tipo III , Pré-Medicação , Ovinos , Nitrito de Sódio/administração & dosagem , Nitrito de Sódio/uso terapêutico , Vasodilatadores/administração & dosagem , Vigília
6.
Best Pract Res Clin Anaesthesiol ; 21(2): 221-39, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17650774

RESUMO

Inherent risks and increasing costs of allogeneic transfusions underline the socioeconomic relevance of safe and effective alternatives to banked blood. The safety limits of a restrictive transfusion policy are given by a patient's individual tolerance of acute normovolaemic anaemia. latrogenic attempts to increase tolerance of anaemia are helpful in avoiding premature blood transfusions while at the same time maintaining adequate tissue oxygenation. Autologous transfusion techniques include preoperative autologous blood donation (PAD), acute normovolaemic haemodilution (ANH), and intraoperative cell salvage (ICS). The efficacy of PAD and ANH can be augmented by supplemental iron and/or erythropoietin. PAD is only cost-effective when based on a meticulous donation/transfusion plan calculated for the individual patient, and still carries the risk of mistransfusion (clerical error). In contrast, ANH has almost no risks and is more cost-effective. A significant reduction in allogeneic blood transfusions can also be achieved by ICS. Currently, some controversy regarding contraindications of ICS needs to be resolved. Artificial oxygen carriers based on perfluorocarbon (PFC) or haemoglobin (haemoglobin-based oxygen carriers, HBOCs) are attractive alternatives to allogeneic red blood cells. Nevertheless, to date no artificial oxygen carrier is available for routine clinical use, and further studies are needed to show the safety and efficacy of these substances.


Assuntos
Doadores de Sangue , Substitutos Sanguíneos/administração & dosagem , Transfusão de Sangue/métodos , Anemia/fisiopatologia , Anemia/terapia , Substitutos Sanguíneos/classificação , Substitutos Sanguíneos/economia , Qualidade de Produtos para o Consumidor/normas , Eritropoetina/administração & dosagem , Hematócrito , Hemodiluição , Hemoglobinas/análise , Humanos , Período Intraoperatório , Oxigênio/sangue , Cuidados Pré-Operatórios , Proteínas Recombinantes
7.
Artigo em Inglês | MEDLINE | ID: mdl-17573626

RESUMO

Hemoglobin-based oxygen carrier-201 transports oxygen and improves survival in swine with hemorrhagic shock, but has potential to be immune activating. Herein, we evaluated HBOC-201's immune effects in swine with more severe hemorrhagic shock due to soft tissue injury and 55% blood volume catheter withdrawal over 15 minutes followed by fluid resuscitation at 20 minutes with HBOC-201, Hextend, or no treatment (NON) before hospital arrival. Survival rates were similar with HBOC-201 and Hextend (p > 0.05), but were higher than in (p = 0.007). There were no significant group differences in blood cell count, percentages of leukocyte sub-populations and immunophenotype (CD4:CD8 ratio), adhesion markers expression (neutrophil CD11b; monocyte or neutrophil CD49d) and apoptosis. There was a trend to higher plasma IL-10 in HBOC-201 and groups vs. Hextend. We conclude that in swine with severe controlled HS and soft tissue injury, immune responses are similar with resuscitation with HBOC-201 and Hextend.


Assuntos
Hemoglobinas/administração & dosagem , Derivados de Hidroxietil Amido/administração & dosagem , Ressuscitação/métodos , Choque Hemorrágico/imunologia , Choque Hemorrágico/terapia , Animais , Apoptose/imunologia , Pressão Sanguínea/fisiologia , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/farmacocinética , Citocinas/imunologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Serviços Médicos de Emergência , Hidratação/métodos , Hemoglobinas/farmacocinética , Imunidade Inata/efeitos dos fármacos , Suínos , Porco Miniatura , Linfócitos T/imunologia , Linfócitos T/patologia
8.
Med Clin (Barc) ; 127 Suppl 1: 3-20, 2006 Jul 18.
Artigo em Espanhol | MEDLINE | ID: mdl-17020674

RESUMO

The Consensus Document on Alternatives to Allogenic Blood Transfusion (AABT) has been drawn up by a panel of experts from 5 scientific societies. The Spanish Societies of Anesthesiology (SEDAR), Critical Care Medicine and Coronary Units (SEMICYUC), Hematology and Hemotherapy (AEHH), Blood Transfusion (SETS) and Thrombosis and Hemostasis (SETH) have sponsored and participated in this Consensus Document. Alternatives to blood transfusion have been divided into pharmacological and non-pharmacological, with 4 modules and 12 topics. The main objective variable was the reduction of allogenic blood transfusions and/or the number of transfused patients. The extent to which this objective was achieved by each AABT was evaluated using the Delphi method, which classifies the grade of recommendation from A (supported by controlled studies) to E (non-controlled studies and expert opinion). The experts concluded that most of the indications for AABT were based on middle or low grades of recommendation, "C", "D", or "E", thus indicating the need for further controlled studies.


Assuntos
Hemorragia/terapia , Ácido Aminocaproico/administração & dosagem , Ácido Aminocaproico/efeitos adversos , Ácido Aminocaproico/uso terapêutico , Antifibrinolíticos/administração & dosagem , Antifibrinolíticos/efeitos adversos , Antifibrinolíticos/uso terapêutico , Aprotinina/administração & dosagem , Aprotinina/efeitos adversos , Aprotinina/uso terapêutico , Perda Sanguínea Cirúrgica/prevenção & controle , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/efeitos adversos , Substitutos Sanguíneos/uso terapêutico , Transfusão de Sangue Autóloga , Coloides/administração & dosagem , Coloides/efeitos adversos , Coloides/uso terapêutico , Soluções Cristaloides , Desamino Arginina Vasopressina/administração & dosagem , Desamino Arginina Vasopressina/efeitos adversos , Desamino Arginina Vasopressina/uso terapêutico , Medicina Baseada em Evidências , Fator VIIa/administração & dosagem , Fator VIIa/efeitos adversos , Fator VIIa/uso terapêutico , Hematínicos/administração & dosagem , Hematínicos/efeitos adversos , Hematínicos/uso terapêutico , Hemodiluição , Hemorragia/tratamento farmacológico , Hemostáticos/administração & dosagem , Hemostáticos/efeitos adversos , Hemostáticos/uso terapêutico , Humanos , Ferro/administração & dosagem , Ferro/efeitos adversos , Ferro/uso terapêutico , Soluções Isotônicas/administração & dosagem , Soluções Isotônicas/efeitos adversos , Soluções Isotônicas/uso terapêutico , Recuperação de Sangue Operatório , Hemorragia Pós-Operatória/tratamento farmacológico , Pré-Medicação , Ensaios Clínicos Controlados Aleatórios como Assunto/estatística & dados numéricos , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Ácido Tranexâmico/administração & dosagem , Ácido Tranexâmico/efeitos adversos , Ácido Tranexâmico/uso terapêutico
9.
Transfusion ; 46(3): 339-47, 2006 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-16533274

RESUMO

BACKGROUND: Hemoglobin-vesicles (HbVs; diameter, 251 +/- 81 nm) are artificial O(2) carriers. Their efficacy for acute exchange transfusion has been characterized in animal models. However subsequent profiles of recovery involving the degradation of HbV in the reticuloendothelial system (RES) and hematopoiesis remain unknown. STUDY DESIGN AND METHODS: Isovolemic 40 percent exchange transfusion was performed in 60 male Wistar rats with HbV suspended in 5 g per dL recombinant human serum albumin (rHSA; HbV/rHSA, [Hb] = 8.6 g/dL), stored rat RBCs suspended in rHSA (sRBC/rHSA), or rHSA alone. Hematological and plasma biochemical analyses and histopathological examination focusing on the spleen were conducted for the subsequent 14 days. RESULTS: The reduced hematocrit (Hct) level (26%) for the HbV/rHSA and rHSA groups returned to its original level (43%) in 7 days. Plasma erythropoietin was elevated in all groups: the rHSA group showed the highest value on Day 1 (321 +/- 123 mIU/mL) relating to the anemic conditions (HbV/rHSA, 153 +/- 22; sRBC/rHSA, 63 +/- 7; baseline, 21 +/- 3). Simultaneously, splenomegaly occurred in all the groups as HbV/rHSA > rHSA > sRBC/rHSA. Histopathologically, the accumulated HbV in the spleen was undetectable by Day 14, but hemosiderin was deposited in slight quantities for both the HbV/rHSA and sRBC/rHSA groups. Considerable amounts of erythroblasts were apparent in the spleens of both the rHSA and the HbV/rHSA groups. CONCLUSION: HbVs were phagocytized and degraded in RES, a physiological compartment for the degradation of RBCs, and the elevated erythropoietic activity resulted in the complete recovery of Hct within 7 days in the rat model.


Assuntos
Substitutos Sanguíneos , Eritropoese/efeitos dos fármacos , Transfusão Total , Hemoglobinas , Albumina Sérica/química , Animais , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/efeitos adversos , Substitutos Sanguíneos/química , Avaliação Pré-Clínica de Medicamentos , Eritroblastos/patologia , Hematócrito , Hemoglobinas/administração & dosagem , Hemoglobinas/efeitos adversos , Hemoglobinas/química , Humanos , Sistema Fagocitário Mononuclear/efeitos dos fármacos , Sistema Fagocitário Mononuclear/patologia , Ratos , Ratos Wistar , Albumina Sérica/administração & dosagem , Baço/efeitos dos fármacos , Baço/patologia
10.
J Appl Physiol (1985) ; 100(1): 336-42, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16166237

RESUMO

The cerebrovascular response to decreases in hematocrit and viscosity depends on accompanying changes in arterial O2 content. This study examines whether 1) the arteriolar dilation seen after exchange transfusion with a 5% albumin solution can be reduced by the K(ATP) channel antagonist glibenclamide (known to inhibit hypoxic dilation), and 2) the arteriolar constriction seen after exchange transfusion with a cell-free hemoglobin polymer to improve O2-carrying capacity can be blocked by inhibitors of the synthesis or vasoconstrictor actions of 20-HETE. In anesthetized rats, decreasing hematocrit by one-third with albumin exchange transfusion dilated pial arterioles (14 +/- 2%; SD), whereas superfusion of the surface of the brain with 10 muM glibenclamide blocked this response (-10 +/- 7%). Exchange transfusion with polymeric hemoglobin decreased the diameter of pial arterioles by 20 +/- 3% without altering arterial pressure. This constrictor response was attenuated by superfusing the surface of the brain with a 20-HETE antagonist, WIT-002 (10 microM; -5 +/- 1%), and was blocked by two chemically dissimilar selective inhibitors of the synthesis of 20-HETE, DDMS (50 microM; 0 +/- 4%) and HET-0016 (1 microM; +6 +/- 4%). The constrictor response to hemoglobin transfusion was not blocked by an inhibitor of nitric oxide (NO) synthase, and the inhibition of the constrictor response by DDMS was not altered by coadministration of the NO synthase inhibitor. We conclude 1) that activation of K(ATP) channels contributes to pial arteriolar dilation during anemia, whereas 2) constriction to polymeric hemoglobin transfusion at reduced hematocrit represents a regulatory response that limits increased O2 transport and that is mediated by increased formation of 20-HETE, rather than by NO scavenging.


Assuntos
Arteríolas/anatomia & histologia , Arteríolas/fisiologia , Substitutos Sanguíneos/administração & dosagem , Ácidos Hidroxieicosatetraenoicos/metabolismo , Pia-Máter/irrigação sanguínea , Pia-Máter/fisiologia , Vasoconstrição/fisiologia , Animais , Transfusão de Sangue Autóloga/métodos , Sistema Livre de Células , Hematócrito , Hemoglobinas/administração & dosagem , Masculino , Ratos , Ratos Wistar
11.
Shock ; 25(1): 50-5, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16369186

RESUMO

HBOC-201, a hemoglobin-based oxygen carrier, improved physiologic parameters and survival in hemorrhagic shock (HS) animal models. However, resuscitation from HS and the properties of different fluids influence immune responses. The aim of this study was to determine if HBOC-201 significantly alters immune function in traumatic HS. Anesthetized pigs underwent soft tissue injury, controlled hemorrhage of 40% of blood volume, and resuscitation with HBOC-201 or Hextend, or no resuscitation. Sequential whole-blood samples were collected for analyses of leukocyte differential (hematology analyzer), T-lymphocyte subsets (CD3, CD4, and CD8) (FACS), lymphocyte adhesion marker CD49d (alpha4-integrin) expression (FACS), plasma cytokines-tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, and IL-10-(ELISA), and lymphocyte apoptosis (annexin-V/propidium iodide staining) (FACS). Statistical analyses were performed by the mixed procedure. Total WBC counts decreased posthemorrhage in both resuscitation groups. Lymphocyte percentages decreased and PMN percentages increased around 4 h posthemorrhage in all groups. CD3 cells decreased in all groups, but CD4 and CD8 cells decreased only in the resuscitation groups. TNF-alpha levels were not detectable in any groups. IL-6 levels were similar across treatment groups (P > 0.05); however, IL-10 levels were higher in the HBOC group, as early as 1 h posthemorrhage (P = 0.04). Increases in lymphocytic CD49d expression levels and apoptosis occurred only in nonresuscitation and Hextend groups, respectively (P < or = 0.01). In comparison with Hextend, HBOC-201 had no significant adverse or beneficial effects on immune function in this model of moderately severe HS in swine, suggesting that it may be safe as a resuscitation fluid in HS patients.


Assuntos
Substitutos Sanguíneos/administração & dosagem , Hemoglobinas/administração & dosagem , Ressuscitação , Choque Hemorrágico/tratamento farmacológico , Choque Hemorrágico/imunologia , Animais , Apoptose/imunologia , Substitutos Sanguíneos/efeitos adversos , Citocinas/imunologia , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Regulação da Expressão Gênica/efeitos dos fármacos , Regulação da Expressão Gênica/imunologia , Hemoglobinas/efeitos adversos , Integrina alfa4/imunologia , Ressuscitação/métodos , Choque Hemorrágico/patologia , Suínos , Linfócitos T/imunologia , Linfócitos T/patologia
12.
Artigo em Inglês | MEDLINE | ID: mdl-16317957

RESUMO

BACKGROUND: HBOC-201 is an ultra purified bovine hemoglobin solution. It has already been used in clinical phase II/III trials for emergency treatments. Animal experiments have shown that HBOC-201 is highly effective in tissue oxygenation. The study was performed in order to assess the potential of low dose HBOC-201 to improve tumor oxygenation. METHODS: 30 rats with a subcutaneously growing rhabdomyosarcoma R1H tumor were randomly assigned either to be ventilated with carbogen (n = 10), or to receive an IV injection of 0.3 g/kg HBOC-201 (n = 10) or a combination of 0.3 g/kg HBOC-201 and carbogen breathing (n = 10). Under general anesthesia the effects of the respective treatment on the tissue oxygen tension (tpO2) of the tumor were determined using a flexible stationary probe at baseline (b) and 15 and 60 min after application of the respective medication. RESULTS: HBOC-201 alone failed to improve tumor tpO2 (b: 1.3 +/- 1.2mmHg; 15min: 1.4 +/- 1 mmHg; 60min: 1 +/- 1 mmHg). In combination with carbogen the mean tpO2 of the tumor raised in comparison to baseline values (b: 3.1 +/- 4.6 mmHg; mmHg; 15min: 8.5 +/- 11*mmHg; 60min: 4.8 +/- 5mmHg; *p < 0.05 vs. b), but this effect was less pronounced than the increase in tpO2 by carbogen alone (b: 3.4 +/- 3.4mmHg; 15min: 9 +/- 10* mmHg; 60 min: 13 +/- 19* mmHg; *p < 0.05 vs. b). CONCLUSION: The application of low dose hemoglobin solution HBOC-201 does not result in improvement of tissue oxygenation in the rat rhabdomyosarcoma R1H.


Assuntos
Hemoglobinas/farmacologia , Oxigênio/metabolismo , Rabdomiossarcoma/metabolismo , Animais , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/farmacologia , Dióxido de Carbono/administração & dosagem , Dióxido de Carbono/farmacologia , Avaliação Pré-Clínica de Medicamentos , Hemoglobinas/administração & dosagem , Hipóxia/tratamento farmacológico , Oxigênio/administração & dosagem , Oxigênio/farmacologia , Ratos , Rabdomiossarcoma/patologia , Distribuição Tecidual/efeitos dos fármacos
13.
Am Heart J ; 149(4): 573-9, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15990736

RESUMO

Despite the availability of interventional catheterization for patients with acute coronary syndromes, there is an unavoidable delay until the occluded coronary artery(s) can be revascularized, during which time persistent ischemia may lead to irreversible myocardial damage despite subsequently high patency rates. Accordingly, there has been an intense effort to develop early interventions that will preserve the viability of ischemic myocardium before revascularization. A number of novel strategies have been studied, including hemoglobin-based oxygen carriers. These compounds transport oxygen in the plasma to help maintain more normal oxygen delivery to the myocardium supplied by a thrombosed vessel, and they also release oxygen to tissue more efficiently than intraerythrocytic hemoglobin.


Assuntos
Substitutos Sanguíneos/uso terapêutico , Cardiotônicos/uso terapêutico , Hemoglobinas/uso terapêutico , Isquemia Miocárdica/terapia , Revascularização Miocárdica , Cuidados Pré-Operatórios , Adulto , Idoso , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/química , Substitutos Sanguíneos/farmacocinética , Cardiotônicos/administração & dosagem , Cardiotônicos/química , Cardiotônicos/farmacocinética , Ensaios Clínicos Fase II como Assunto , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Feminino , Hemoglobinas/administração & dosagem , Hemoglobinas/química , Hemoglobinas/farmacocinética , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Infarto do Miocárdio/tratamento farmacológico , Infarto do Miocárdio/cirurgia , Infarto do Miocárdio/terapia , Isquemia Miocárdica/tratamento farmacológico , Isquemia Miocárdica/cirurgia , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Miocárdio/metabolismo , Oxigênio/metabolismo , Projetos Piloto , Ensaios Clínicos Controlados Aleatórios como Assunto
14.
J Am Coll Surg ; 198(3): 373-83; discussion 384-5, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-14992738

RESUMO

BACKGROUND: The benefits of intraoperative autologous donation (IAD) in reducing the need for allogeneic blood transfusion in surgery have been debated for several years. The purpose of this study was to determine if IAD alone or in conjunction with hemoglobin raffimer (HR) confers a reduction in red cell or blood component transfusion compared with results in standard clinical practice. STUDY DESIGN: The Phase III clinical trial was a multicenter, randomized, double-blind study to determine the efficacy and safety of HR versus 10% pentastarch when used to facilitate IAD in 299 patients undergoing primary coronary artery bypass grafting. The patients received HR or pentastarch as an adjunct to IAD immediately before cardiopulmonary bypass. Results were compared with transfusion requirements for 150 matched patients in the reference group. RESULTS: The frequency of allogeneic RBC transfusion in the HR, pentastarch, and reference groups was 56%, 76%, and 95%, respectively. The number of allogeneic red cell units used was 49 in the HR group, 104 in the pentastarch group, and 480 in the reference group (p < 0.001). The total number of non-RBC units administered was 150 in the HR group, 238 in the pentastarch group, and 270 in the reference group. CONCLUSIONS: In this study, patients treated with HR in conjunction with IAD received fewer transfusions overall and a lower volume of allogeneic RBCs and non-RBC allogeneic blood products than did the two comparison groups. This confers a real benefit on the overall blood supply by decreasing use and increasing availability.


Assuntos
Transfusão de Sangue Autóloga , Ponte de Artéria Coronária/métodos , Estenose Coronária/cirurgia , Hemoglobinas/administração & dosagem , Rafinose/análogos & derivados , Rafinose/administração & dosagem , Idoso , Substitutos Sanguíneos/administração & dosagem , Substitutos Sanguíneos/efeitos adversos , Transfusão de Sangue/estatística & dados numéricos , Transfusão de Sangue Autóloga/estatística & dados numéricos , Estenose Coronária/sangue , Método Duplo-Cego , Transfusão de Eritrócitos/estatística & dados numéricos , Feminino , Humanos , Derivados de Hidroxietil Amido , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
16.
Transfus Med ; 12(5): 311-6, 2002 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-12383337

RESUMO

Diaspirin cross-linked haemoglobin (DCLHb) is a haemoglobin-based oxygen carrier which had been proposed as a resuscitative solution to replace red cell transfusion in many clinical situations. The present study was designed to evaluate the effect of different volumes of DCLHb 10% (1, 5 and 10 mL kg-1) on the cardiovascular system during cardiopulmonary bypass (CPB), and to determine the effect of DCLHb (18 mL kg-1) when added directly to the CPB prime in anaesthetized swine. DCLHb, when used as a priming solution, induced a significant increase (around 20%) in mean arterial pressure (MAP), which persisted during the entire period of CPB (P < 0.05) as compared with controls. Administration of increasing doses of DCLHb during the time course of CPB resulted in a progressive increase in MAP (P < 0.05), suggesting a linear dose-response relationship. Nicardipine, a calcium channel blocker, returned MAP to baseline. Finally, weaning of CPB was easier in animals that received DCLHb, thereby suggesting a potential protective effect of free haemoglobin in this particular clinical situation.


Assuntos
Aspirina/análogos & derivados , Aspirina/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Substitutos Sanguíneos/farmacologia , Ponte Cardiopulmonar/métodos , Hemoglobinas/farmacologia , Animais , Artérias/fisiologia , Aspirina/administração & dosagem , Gasometria , Substitutos Sanguíneos/administração & dosagem , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Hemoglobinas/administração & dosagem , Nicardipino/administração & dosagem , Nicardipino/farmacologia , Assistência Perioperatória , Suínos
18.
Crit Care Med ; 26(12): 2037-41, 1998 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-9875917

RESUMO

OBJECTIVES: The density of perfluorocarbons is almost twice that of blood. Therefore, we hypothesized that partial liquid ventilation with these fluids markedly affects pulmonary hemodynamics and filtration coefficients. To test these hypotheses we studied pressure-flow relationships, vascular compliances, capillary pressures, and filtration coefficients in normal and perfluorocarbon-ventilated rabbit lungs. DESIGN: Controlled animal study with an ex-vivo isolated lung preparation. SETTING: Research laboratory for experimental anesthesiology at the Heinrich-Heine-University of Düsseldorf. SUBJECTS: Fourteen New Zealand White rabbits. INTERVENTIONS: The lungs were perfused under zone 3 flow conditions with autologous blood at various flow rates (50 to 250 mL/min, closed circuit, roller pump, 37 degrees C) and ventilated with 5% CO2 in air (positive end-expiratory pressure: 2 cm H2O, tidal volume: 10 mL/kg, respiratory rate: 30 breaths/min) without (control group, n=7) and with (n=7) perfluorocarbon administered intratracheally (15 mL/kg). MEASUREMENTS AND MAIN RESULTS: Pulmonary arterial, left atrial, and airway pressures, as well as blood reservoir volume (reflecting changes in pulmonary blood volume) and lung weight, were measured continuously. Inconsistent with our hypothesis, we found no significant differences between both groups in the slopes and intercepts of the pressure-flow relationships. There were no significant differences in capillary pressures determined by double occlusion (6.7+/-1.2 vs. 6.3+/-1.3 cm H2O for control group, p=.53), vascular compliances (0.51+/-0.10 vs. 0.47+/-0.09 mL/cm H2O for control group, p=.38), and filtration coefficients (0.33+/-0.06 vs. 0.37+/-0.07 mL/min/mm Hg/100 g wet weight for control group, p=.80, Mann-Whitney). CONCLUSIONS: Partial liquid ventilation with perfluorocarbons has no relevant effects on pulmonary filtration coefficients and global hemodynamic variables of isolated zone 3 lungs. These findings suggest that right ventricular afterload is not changed with partial liquid ventilation. It is likely, however, that intrapulmonary blood flow is redistributed toward less-dependent regions, although relevant global hemodynamic changes are absent during partial liquid ventilation.


Assuntos
Substitutos Sanguíneos/farmacologia , Fluorocarbonos/farmacologia , Circulação Pulmonar/efeitos dos fármacos , Pressão Propulsora Pulmonar/efeitos dos fármacos , Respiração Artificial/métodos , Animais , Substitutos Sanguíneos/administração & dosagem , Avaliação Pré-Clínica de Medicamentos , Feminino , Fluorocarbonos/administração & dosagem , Hemodinâmica/efeitos dos fármacos , Técnicas In Vitro , Instilação de Medicamentos , Masculino , Coelhos , Distribuição Aleatória , Resistência Vascular/efeitos dos fármacos
20.
Crit Care Med ; 24(4): 663-71, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8612420

RESUMO

OBJECTIVE: To test the effects of three hemoglobin solutions on liver function and hepatic morphology after resuscitation from severe hemorrhagic shock. DESIGN: Prospective study. SETTING: Laboratory. SUBJECTS: Thirty-three beagle dogs. INTERVENTION: Hemorrhagic shock was induced in anesthetized dogs by removal of blood at a rate of 2 mL/kg/min until systolic blood pressure (BP) reached 50 mm Hg. BP was maintained at this level 2 hrs by further withdrawing 5 to 10 mL aliquots whenever BP increased > 50 mm Hg. Resuscitation was then initiated with autologous whole blood (n = 7), 4% pyridoxalated-hemoglobin-polyoxyethylene conjugate (4% PHP [n = 6]), 8% pyridoxalated-hemoglobin-polyoxyethylene conjugate (8% PHP [n = 9], or 8% stroma-free hemoglobin (n = 7). Four dogs were managed identically but were not resuscitated. Gross necropsy and histologic examination of the liver were performed on all dogs after 7 days, or earlier if death occurred. MEASUREMENTS AND MAIN RESULTS: In vitro interferences of PHP and stroma-free hemoglobin with liver function tests were determined and recommendations for interpretation of results from blood samples containing PHP and stroma-free hemoglobin were made. Blood was collected before, during, and after resuscitation from hemorrhagic shock. The dogs were then awakened and survivors were monitored daily with blood sampling until they were killed and necropsy was performed. After 7 days, the survival rate following hemorrhagic shock was 100% for whole blood and 4% PHP, 86% for stroma-free hemoglobin, and 33% for 8% PHP. Of the resuscitated dogs not surviving 7 days, all but one died within 27 hrs from coagulopathy. All dogs not resuscitated died within 1.75 hrs after 2 hrs of shock. Bilirubin, alkaline phosphatase, and lactic dehydrogenase concentrations could not be measured due to interferences of stroma-free hemoglobin and PHP. Aspartate (AST) and alanine (ALT) aminotransferase concentrations could be measured after dilution to overcome the interferences. Significant increases in AST and ALT values in all groups 24 hrs after resuscitation were attributed to hypoxic hepatocellular damage associated with the severity of the shock model rather than to the resuscitation fluid. Liver histology showed no changes attributed to toxic damage of hepatocytes in dogs resuscitated with stroma-free hemoglobin or PHP. However, changes, were less severe in dogs resuscitated with 4% PHP than in other groups. CONCLUSION: Morphologic studies at necropsy and liver function tests in dogs receiving hemoglobin solutions, compared with autologous blood, support the conclusion that the PHP and stroma-free hemoglobin solutions tested did not produce hepatic toxicity when used as resuscitation fluids in this model of severe shock.


Assuntos
Substitutos Sanguíneos/administração & dosagem , Transfusão de Sangue Autóloga/métodos , Hemoglobinas/administração & dosagem , Fígado/fisiopatologia , Polietilenoglicóis/administração & dosagem , Ressuscitação/métodos , Choque Hemorrágico/fisiopatologia , Choque Hemorrágico/terapia , Doença Aguda , Animais , Substitutos Sanguíneos/toxicidade , Modelos Animais de Doenças , Cães , Avaliação Pré-Clínica de Medicamentos , Hemoglobinas/toxicidade , Fígado/patologia , Polietilenoglicóis/toxicidade , Estudos Prospectivos , Choque Hemorrágico/mortalidade , Choque Hemorrágico/patologia , Soluções , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA